Qiming Venture Partners Weekly | Portfolio News and Updates Vol. 09, 2025
Celebrating milestone moments with Qiming Venture Partners' portfolio companies
Editor's Note: The "Qiming Weekly" column publishes regularly every week, rounding up funding news and development updates from Qiming Venture Partners' portfolio companies.
Every step entrepreneurs take amid the waves of technology and innovation deserves to be documented. Qiming Venture Partners will continue to accelerate and empower founders, and we invite you to join us in marking the milestone moments of our portfolio companies.
Funding News
01/
Wushuang Medical Closes Nearly RMB 150 Million Series C Round
Qiming Venture Partners Continues Investment
Wushuang Medical, a Qiming Venture Partners portfolio company, recently announced the completion of a nearly RMB 150 million Series C round. Qiming Venture Partners previously led the Series A, co-led the Series B, and continued to invest in the B+ round and this round. Proceeds will fund R&D and commercialization of Wushuang Medical's next-generation products.
Wushuang Medical is a leader in independently developed and manufactured cardiac rhythm management (CRM) medical devices in China, dedicated to building a high-end domestic CRM medical device brand. Its product portfolio covers implantable cardioverter defibrillators (ICDs), implantable cardiac monitors (ICMs), and pacemakers. Bringing together experts from China and the US, the company has accumulated deep technical expertise and industry solutions experience over eight years, forming core capabilities and implementation methodologies spanning the full CRM system lifecycle.
Ao Zhang, Partner at Qiming Venture Partners, said: "China's cardiovascular medical device market is highly competitive, but the cardiac rhythm management segment still holds underexplored opportunities. As a leader in this field, Wushuang Medical has continued to win market favor through its forward-looking positioning and core technology innovation capabilities. Since 2020, Qiming Venture Partners has invested in Wushuang Medical three times, witnessing the company's successful completion of ICD and ICM clinical trials and its ongoing efforts to meet the growing cardiac rhythm management needs of Chinese patients. Qiming Venture Partners will continue to support Wushuang Medical's independent innovation, and we hope the company will continue to introduce globally innovative products such as novel pacing systems to benefit patients worldwide."
02/
Tuepm Medical Raises RMB 500 Million Series E
Qiming Venture Partners Co-Invests
Tuepm Medical recently completed a RMB 500 million Series E round co-invested by Qiming Venture Partners. This marks the company's second round from top-tier investors within a year, following its Series D in June 2024. It is also the largest disclosed primary-market financing round in the history of China's ophthalmic medical equipment sector. Proceeds will be used to expand Tuepm Medical's product matrix and strengthen its global market presence.
Tuepm Medical currently has four commercialized high-end equipment product lines: ophthalmic OCT, ophthalmic surgical microscopes, ultra-widefield fundus cameras, and optical biometers. Its phaco-vitrectomy system and femtosecond laser products are still in development. To date, Tuepm Medical is one of the very few "full-platform" high-end ophthalmic instrument suppliers globally that can match the full product lines of Zeiss and Alcon.
Shuo Mao, Executive Director at Qiming Venture Partners, said: "We are honored to partner with the Tuepm Medical team. The company has rapidly broken through the competition from numerous foreign brands in the high-end ophthalmic equipment track. Over the past year, it has also continued to push new product launches and expand overseas. We look forward to seeing the company achieve more milestones and build a global Tuepm brand."
03/
Insilico Medicine Raises $110 Million Series E
Accelerating AI and Robotics-Driven Drug R&D Innovation
Insilico Medicine, a Qiming Venture Partners portfolio company, recently announced the completion of a $110 million Series E round. Qiming Venture Partners led the Series B and continued to invest in the Series C and D rounds.
Proceeds will drive breakthroughs in Insilico Medicine's AI platform upgrades and drug pipeline innovation. On one hand, funds will be used to refine the company's proprietary AI models and algorithms, while upgrading and expanding its leading automated robotics laboratory to further automate and optimize R&D workflows. On the other hand, Insilico Medicine will focus on advancing clinical validation of its core candidate drug for idiopathic pulmonary fibrosis (IPF) and accelerating exploration of other self-developed and partnered drug pipelines, driving breakthrough innovation in biopharmaceutical R&D.
Pharma.AI is Insilico Medicine's self-developed platform, maintaining its technological leadership through two major updates per year. Centered on generative AI and continuously incorporating cutting-edge technologies, the Pharma.AI platform provides integrated solutions spanning biology, generative chemistry, clinical medicine, and scientific research.
To date, powered by the Pharma.AI platform, Insilico Medicine has rapidly built a pipeline of over 30 drug programs, with 10 projects obtaining clinical trial approvals. Among these, the most advanced candidate is Rentosertib (ISM001-055) for idiopathic pulmonary fibrosis (IPF), which has progressed through multiple clinical studies with encouraging results. In a recently completed Phase 2a clinical trial, Rentosertib demonstrated good safety and tolerability at all dose levels, while subjects showed dose-related improvements in forced vital capacity (FVC) after 12 weeks of continuous dosing.
Major Partnerships
01/
Hesai Technology Secures Multi-Year Exclusive Design Win with European Top-Tier OEM
Hesai Technology (NASDAQ: HSAI), a Qiming Venture Partners portfolio company and global leader in lidar, recently announced a landmark multi-year exclusive design win with a European top-tier OEM. Hesai will provide high-performance ultra-long-range lidar for the automaker's next-generation vehicle platforms, covering multiple models across both ICE and NEV lineups. This long-term collaboration extends beyond 2030 and represents the largest order to date in the overseas series-production lidar sector, further underscoring Hesai Technology's leading position in the global market.
As of February 2025, Hesai Technology has secured series-production design wins with 22 domestic and international automakers for 120 vehicle models, fully demonstrating its leading technical advantages and market recognition. In December 2024, Hesai Technology's monthly shipments exceeded 100,000 units, making it the world's first lidar company to achieve monthly deliveries surpassing 100,000 units.
02/
Easyhome Smart Home and UBTECH Sign Strategic Partnership Agreement
Recently, Easyhome Smart Home and UBTECH (09880.HK), a Qiming Venture Partners portfolio company, formally signed a strategic partnership agreement. Both parties will uphold a win-win cooperation philosophy to drive intelligent upgrading in the smart home industry and fully integrate intelligent robots into the home furnishing industry and household scenarios.
Under the strategic cooperation agreement, both parties will jointly advance the deployment of humanoid robots in Easyhome Smart Home's new retail stores and other commercial sales scenarios. Easyhome Smart Home plans to purchase and deploy 500 UBTECH humanoid robots by the end of 2025 to enhance customer shopping experiences and create new smart consumption scenarios. Easyhome Smart Home will also promote UBTECH's humanoid robots, with plans to sell 10,000 units during the strategic cooperation period.
Easyhome Smart Home will actively promote the application of UBTECH's intelligent eldercare robots in home service environments and related eldercare scenarios to meet the growing demand for intelligent eldercare services.
Additionally, both parties plan to jointly develop renovation robots by combining UBTECH's advantages in humanoid robot core technologies with Easyhome Smart Home's scenario needs in home furnishing, AI design, and smart renovation experience — helping the renovation industry reduce costs and improve efficiency, driving the transformation of Easyhome Smart Home's business model, and enhancing user renovation experiences.
03/
StepFun and AgiBot Reach Deep Strategic Partnership
Recently, Qiming Venture Partners portfolio company StepFun and AgiBot formally signed a deep strategic cooperation agreement. The two parties will combine their strengths in foundation large models and robot R&D, jointly exploring world model technology, data cooperation in embodied intelligence, and application scenarios such as new retail — together advancing technological breakthroughs and application innovation in "large models + embodied robots."
Specifically, StepFun and AgiBot's strategic cooperation extends to multiple dimensions including model R&D, industry solutions, and data systems. This includes jointly exploring 4D world model development, exploring the application of embodied intelligence in smart marketing and supply chain management under new retail scenarios, and advancing the establishment of data-related standards and evaluation dataset systems in the embodied intelligence field.
04/
Superhexa Partners with Huaxia Eye Hospital Group
to Explore New Model Integrating Smart Glasses with Ophthalmic Care
Recently, Qiming Venture Partners portfolio company Superhexa formally reached a strategic cooperation with Huaxia Eye Hospital Group. Both parties will carry out in-depth cooperation in smart glasses technology R&D, ophthalmic medical applications, and professional fitting services. They will jointly explore new models, standards, and possibilities for integrating "smart glasses + professional fitting" in technology R&D, data sharing, and application implementation — committed to providing patients with one-stop eyewear services including smart glasses trial wear, eye health screening, and professional optometry.
This cooperation represents Superhexa's new exploratory partnership with the ophthalmic medical industry, marking another important step for Superhexa in the visual health field.
R&D Progress
01/ Gan & Lee Pharmaceuticals Holds Investigator Meeting
for Phase 3 Clinical Trial of Bempedoic Acid Tablets
Recently, Qiming Venture Partners portfolio company Gan & Lee Pharmaceuticals (603087.SH) successfully hosted the investigator meeting for the Phase 3 clinical trial of bempedoic acid tablets in Beijing. The meeting invited over 50 clinical investigators from 27 hospitals nationwide to participate in discussions.
This national investigator meeting conducted in-depth discussions around the R&D progress of bempedoic acid tablets, key data interpretation, and optimization of the Phase 3 clinical trial protocol, providing important guidance for subsequent project advancement. The successful hosting of this meeting not only laid a solid foundation for the smooth progress of Gan & Lee Pharmaceuticals' Phase 3 clinical trial of bempedoic acid tablets, but also established a high-level academic exchange platform promoting deep integration of industry, academia, and research.
02/ Gan & Lee Pharmaceuticals Completes First Dosing in US Phase 2
Obesity/Overweight Clinical Study for Bofanglutide Injection
Recently, Qiming Venture Partners portfolio company Gan & Lee Pharmaceuticals (603087.SH) announced that its self-developed glucagon-like peptide-1 receptor agonist (GLP-1RA) biweekly formulation, bofanglutide (development code: GZR18) injection, has completed first subject dosing in its Phase 2 clinical study in obese/overweight subjects in the United States. This also marks the world's first single-target GLP-1RA to conduct a head-to-head evaluation of weight loss efficacy against tirzepatide.
Previously, bofanglutide injection had completed a Phase 1 study in healthy US subjects (clinical trial registration number: NCT06548997). Study results showed that bofanglutide injection demonstrated good safety and tolerability in US subjects, with excellent potential for blood glucose reduction and weight loss. The company's initiation of this head-to-head study against tirzepatide marks a new stage in Gan & Lee Pharmaceuticals' GLP-1 innovation, challenging the leading position of globally dominant GLP-1 products for weight loss, with the aim of providing better treatment options for obese patients worldwide.
03/ Zai Lab's Tisotumab Vedotin BLA for Recurrent or
Metastatic Cervical Cancer Accepted for Review
Recently, Qiming Venture Partners portfolio company Zai Lab (NASDAQ:ZLAB, 09688.HK) announced that the National Medical Products Administration (NMPA) has accepted the biologics license application (BLA) for tisotumab vedotin for the treatment of patients with recurrent or metastatic cervical cancer whose disease has progressed on or after systemic therapy.
Dr. Rafael G. Amado, President and Global Head of R&D at Zai Lab, stated: "In China, cervical cancer is a serious health issue with approximately 150,000 newly diagnosed cases each year. For patients who experience recurrence or metastasis after initial treatment, there are limited treatment options. Tisotumab vedotin is currently the only antibody-drug conjugate (ADC) therapy for cervical cancer, showing promising benefit in the pivotal global innovaTV 301 study, including clinically meaningful improvement in overall survival (OS). If approved, tisotumab vedotin will leverage our existing Zejula commercial infrastructure to expand our ability to provide treatment for patients with gynecological cancers."
04/ Transcription Biotech Announces First Circular RNA Drug
for Radiation-Induced Xerostomia Completes First Patient Dosing
Recently, Qiming Venture Partners portfolio company Transcription Biotech announced that its globally first-in-class circular RNA drug, RXRG001, has completed first patient dosing in its Phase 1/2a clinical study (SPRINX-1), aimed at evaluating the safety and efficacy in patients with radiation-induced xerostomia following dosing.
RXRG001 is a circular RNA drug developed independently by Transcription Biotech, encapsulated in lipid nanoparticles (LNP). It delivers circular RNA via LNP to express aquaporin-1 (AQP1) in salivary glands, enhancing water permeability and thereby increasing saliva flow rate and volume into the oral cavity to alleviate dry mouth symptoms. Non-clinical studies have demonstrated durable efficacy along with favorable tolerability and safety. A single administration significantly increased saliva flow, with effects lasting up to four weeks. RXRG001 received FDA approval in October 2024, becoming the world's first circular RNA therapy permitted by the FDA to enter clinical trials.
05/ M20 Genomics Spatial Full-Length Transcriptomics Technology
Helps Decode Spatial Heterogeneity in Gynecological Tumors
In a study of intratumoral spatial heterogeneity in gynecological malignancies, a research team used M20 Genomics's M20 Spatial technology — a Qiming Venture Partners portfolio company — to test FFPE samples from endometrial and ovarian cancers.
M20 Spatial is the world's first random-primer-based spatial full-length transcriptomics technology applicable to whole samples, including FFPE tissue. It can simultaneously capture mRNA and non-coding RNA, ushering spatial transcriptomics into a new era of multi-species, whole-sample, whole-transcriptome, and full-length sequencing.
The newly released test data from FFPE samples of gynecological malignancies including endometrial and ovarian cancers confirms that M20 Spatial delivers exceptional performance across diverse clinical samples and provides novel insights into tumor heterogeneity and disease molecular characteristics.
06/
BioTree Biotech Collaborative Research Published in
International Renowned Academic Journal
Recently, a paper led by Professor Li Xin, chief expert of Guangdong's medical aid to Tibet and emergency department physician at Guangdong Provincial People's Hospital, together with the research team of Liu Zhipeng at BioTree Biotech's Metabolomics Technology Research Center — a Qiming Venture Partners portfolio company — and multiple institutions including Nyingchi People's Hospital, was published in the international renowned academic journal Redox Biology.
The study shows that moderate-altitude exposure induces changes in serum uric acid and metabolomics profiles in humans. Both in vivo and in vitro experiments demonstrate that β-alanine intervention can improve hyperuricemia. Furthermore, a prediction model based on serum metabolites and clinical indicators can help identify the risk of asymptomatic hyperuricemia during moderate-altitude exposure. These findings may open new avenues for preventing and treating hyperuricemia and its related diseases.
Product Launches
01/
UBTECH Partners with Beijing Humanoid Robot Innovation Center to Launch Full-Size Research and Education Humanoid Robot "Tiangong Xingzhe"
Recently, Qiming Venture Partners portfolio company UBTECH (09880.HK) jointly launched "Tiangong Xingzhe," a full-size research and education humanoid robot, with the Beijing Humanoid Robot Innovation Center (hereinafter "the Innovation Center"). Positioned as a high-value offering to reshape the humanoid robot research and education ecosystem, UBTECH will begin deliveries in the second quarter.
Designed to accommodate the broad research demands of the academic and education sector, the Tiangong Xingzhe chassis is freely expandable and can be equipped with core humanoid robot components including depth cameras, LiDAR, NVIDIA Orin compute boards, six-axis force sensors, seven-degree-of-freedom collaborative dual arms, and five-finger dexterous hands. The platform also fully opens底层 motor interfaces, sensor interfaces, and motion control interfaces, supported by comprehensive development guides and sample code, fully satisfying secondary development needs for researchers in embodied AI body control, high-precision motion control, and related fields.
Beyond the joint launch of the full-size research-grade humanoid robot with the Innovation Center, UBTECH has established a "Humanoid Robot Research Co-Development Fund" aimed at accelerating research innovation and scenario-based innovation. Open to universities and research institutions worldwide, the fund supports national and industry-level standards, research projects, competitions, and other specialized initiatives.
02/
Pulnovo Medical's PHD360 Pulmonary Artery Radiofrequency Ablation System and PFlexi Sheath Access Product Receive Regulatory Approval
Recently, Qiming Venture Partners portfolio company Pulnovo Medical announced that its PHD360 pulmonary artery radiofrequency ablation system has been formally approved by China's National Medical Products Administration (NMPA). As the next-generation product following the pulmonary artery radiofrequency ablation system that received innovative approval in 2023, the PHD360 adds temperature-controlled mode, further enhancing ablation precision and safety for a more controllable and efficient treatment experience.
Additionally, Pulnovo Medical's self-developed access product, the PFlexi sheath, has received marketing approval from both the FDA and China's NMPA. This dual-channel approval provides stable and reliable device access for pulmonary artery interventional procedures. From pulmonary artery radiofrequency ablation system 1.0 to 2.0, and from ablation devices to access products, Pulnovo Medical is driving growth through a "device + access" dual-engine strategy, building systematic solutions to help pulmonary hypertension and heart failure patients access safer and more effective interventional treatment options.
03/
Gan & Lee Pharmaceuticals' Insulin Aspart 30 Formulation Approved in Malaysia
Recently, Qiming Venture Partners portfolio company Gan & Lee Pharmaceuticals (603087.SH) announced that its insulin aspart 30 formulation, developed in partnership with a local Malaysian pharmaceutical company, has received registration approval from Malaysia's National Pharmaceutical Regulatory Agency. This marks the first overseas approval for Gan & Lee's insulin aspart 30 product, representing a significant milestone in the company's internationalization strategy and laying a solid foundation for further expansion into Southeast Asian markets.
As a member of PIC/S (The Pharmaceutical Inspection Co-operation Scheme), Malaysia maintains a rigorous drug regulatory system. The successive approvals of Gan & Lee's products demonstrate the company's comprehensive capabilities in international quality standards, production processes, and global registration, while also providing local patients with treatment options offering greater overall benefits and further meeting patient medication needs.
04/
Dingke Medical's DKutting® High-Pressure Scoring Balloon Receives EU CE MDR Certification
Recently, the DKutting® scoring balloon dilation catheter, independently developed by Qiming Venture Partners portfolio company Dingke Medical, successfully obtained EU CE MDR certification (CE: M.2025.MDR.1065). This certification represents a steady advance into the EU market and other countries and regions recognizing this certification, formally securing market access qualification. Going forward, the product will showcase China's independent medical device R&D capabilities and exceptional product quality on the international stage.
The DKutting® High-Pressure Scoring Balloon is an innovative product from DK Medical, featuring an exclusive patented design with excellent deliverability and directional dilation capabilities. The product employs a scoring element crafted with "triangular nitinol coiled spring" technology — its cross-section forms an equilateral triangle, with three scoring elements positioned at 120° intervals and firmly fixed to the balloon's working segment. This design prevents scoring element slippage during dilation of highly resistant stenotic lesions, while the triangular geometry efficiently embeds into the vascular intima. Combined with a rated burst pressure of 20 atm, it delivers comprehensive localized high pressure for directional dilation. Additionally, the patented nitinol coiled spring design significantly enhances balloon deliverability for highly stenotic tortuous lesions.
Technology Strength
01/ WeRide Helps Launch Spain's First Public Road Pre-Mass-Production Autonomous Driving Trial Service
Recently, Qiming Venture Partners portfolio company and global leading autonomous driving technology company WeRide (NASDAQ: WRD) announced the launch of an autonomous shuttle (Robobus) trial service in downtown Barcelona in partnership with Renault Group. This marks Spain's first public road pre-mass-production autonomous driving trial service, fully demonstrating WeRide's autonomous driving technical capabilities in high-density, complex urban traffic scenarios.
"This Barcelona trial represents another important achievement in WeRide's internationalization strategy, showcasing our technical leadership as we expand from Asian markets into core European markets," said Tony Han, WeRide's Founder and CEO. "This is not only recognition of our technical maturity but also an upgrade of our strategic partnership. The French Open project validated our vehicles' feasibility in large-scale event scenarios, and this Spain trial extends to downtown public transportation, laying a solid foundation for our 2030 strategic goals and further demonstrating WeRide's concrete efforts toward our vision of making driverless mobility benefit people worldwide."
Entering 2025, WeRide's commercial deployment in Europe is gaining unstoppable momentum. On February 28, WeRide partnered with beti, Renault Group, and Macif to launch Europe's first L4 autonomous shuttle fully unmanned commercial operation line in France's Drôme department. In January, WeRide collaborated with Zurich Airport and Swiss Transit Lab (STL) to launch Europe's first airport autonomous shuttle testing operation. In the same month, WeRide announced a partnership with Swiss Federal Railways SBB, with plans to deploy a Robotaxi fleet to serve residents of the Furttal region in Q2 2025.
02/
Shengshu Technology Presents at 2025 NVIDIA Inception Showcase Wuhan
Recently, the 2025 NVIDIA Inception Showcase Wuhan, hosted by NVIDIA and co-hosted by Wuhan Industrial Innovation and Development Research Institute with support from Google Cloud and others, was officially held. Qiming Venture Partners portfolio company Shengshu Technology, a leading large model enterprise in the global AI video generation field, was invited to participate. Jiayu Tang, Co-founder and President of Shengshu Technology, delivered a keynote speech titled "Shengshu Goes Global: Innovative Breakthroughs and Global Opportunities in AI Video Generation Technology."
In his speech, Tang noted that since the official release of Shengshu Technology's video large model Vidu in April 2024, it has rapidly garnered widespread global attention. As China's first long-duration, high-consistency, high-dynamics video large model, Vidu has continuously released technically leading achievements based on its original U-ViT architecture. The newly released Vidu 2.0 in January 2025 achieved a key breakthrough in generation speed, pushing video generation into the "second-era." Currently, Vidu covers over 200 countries and regions, surpassing 10 million users within 100 days of launch — the fastest user growth globally.
03/
Frontis Achieves CMMI Level 3 Certification, R&D Capability Maturity Reaches International Standards
Recently, Qiming Venture Partners portfolio company Frontis officially obtained CMMI Level 3 certification, marking that its software R&D capabilities, project management standards, and service delivery quality have reached internationally recognized benchmarks.
CMMI (Capability Maturity Model Integration) is an authoritative certification developed by the Software Engineering Institute at Carnegie Mellon University in the United States, widely recognized as the international standard for measuring software enterprise R&D capability maturity. Enterprises achieving CMMI Level 3 certification demonstrate comprehensive and standardized capabilities across 18 process domains including requirements management, project planning, risk control, and quality assurance — proving their ability to efficiently deliver high-quality software products and services.
04/
HyperStrong's Königssee Independent Energy Storage Project in Germany Achieves Major Progress
Recently, Qiming Venture Partners portfolio company HyperStrong (688411.SH) achieved major progress on its Königssee independent energy storage project in Germany. The project successfully completed all installation and commissioning tasks in February 2025 and has now entered the trial operation phase.
The Königssee independent energy storage project has a capacity of 10.35MW/22.36MWh and is equipped with HyperStrong's HyperBlock II liquid-cooled energy storage system. As HyperStrong's flagship large-scale storage product, HyperBlock II delivers outstanding performance with significant advantages including high maturity, safety and reliability, low LCOS, long lifespan, and strong environmental adaptability. The system employs a combined fire protection solution of cabin-level aerosol, combustible gas detection, and water fire suppression sprinklers, complemented by HyperStrong AI Cloud Platform's automatic inspection and remote O&M capabilities, enabling efficient early warning and timely elimination of fire hazards — providing solid assurance for the safe and stable operation of the energy storage facility.
05/
Mech-Mind Robotics Showcases at Smart Factory+Automation World 2025 in Korea
At Smart Factory+Automation World 2025 in Korea, Qiming Venture Partners portfolio company Mech-Mind Robotics presented over ten AI+3D product units, launching immersive scenario-based demonstrations in automotive manufacturing, precision welding, home appliance assembly, industrial quality inspection, and other fields.
Mech-Mind Robotics' Korean subsidiary has established a comprehensive sales, technical, and training service system, along with a camera inventory management system to ensure timely project delivery. The company has developed in-depth partnerships with numerous leading Korean robot manufacturers, distributors, and system integrators, with rapid business progress.
06/
SinoUnited Health Performs Shanghai's First Arthroscopic InSpace Biodegradable Balloon Implantation
Recently, the orthopedic sports medicine expert team at Qiming Venture Partners portfolio company SinoUnited Health successfully performed Shanghai's first arthroscopic InSpace biodegradable balloon implantation for a patient with irreparable massive rotator cuff tear. This represents a major breakthrough in shoulder disease treatment technology in Shanghai's high-end private healthcare sector and demonstrates SinoUnited Health's robust capabilities in minimally invasive surgical treatment of sports injuries.
Dr. Haoying Shi, Founder and CEO of SinoUnited Health, stated: "SinoUnited Health will continue to introduce globally advanced therapies and enable more patients to access high-quality medical services through multidisciplinary team (MDT) models and full-process refined management."
07/
SinoCellTech's Anyouping® First Batch of Products Successfully Shipped, Commercialization Process Begins
Finolimumab (Anyouping®), a recombinant humanized anti-PD-1 monoclonal antibody developed by Qiming Venture Partners portfolio company SinoCellTech (688520.SH), received approval in February for both head and neck squamous cell carcinoma and liver cancer indications. The first batch of products has recently completed production and quality inspection, officially launching nationwide distribution.
Recently, Anyouping® issued its first prescriptions in Beijing, Hebei, and other regions, marking the drug's formal entry into clinical use and providing a new treatment option for patients who meet the indicated criteria.
08/
CANbridge's Velaglucerase Alfa for Injection Passes Segmented Manufacturing Pilot Inspection
Recently, Qiming Venture Partners portfolio company CANbridge Pharmaceuticals (01228.HK) announced that its wholly-owned subsidiary — CANbridge (Shanghai) Biopharmaceuticals Co., Ltd., as the marketing authorization holder — successfully passed the collaborative inspection of its segmented manufacturing pilot program. The inspection was coordinated by the Center for Food and Drug Inspection of the National Medical Products Administration, with joint participation from the Shanghai Center for Drug Evaluation and Inspection and the Jiangsu Provincial Medical Products Administration Inspection Center, covering both registration inspection and pre-market GMP compliance inspection.
Velaglucerase Alfa for Injection is the first innovative biologic in China to pass segmented manufacturing inspection, and the first domestically developed recombinant human glucocerebrosidase replacement therapy for Type I and Type III Gaucher disease patients to enter clinical application. Most Gaucher disease patients have Type I or Type III, corresponding to chronic non-neuronopathic and chronic neuronopathic forms respectively. Velaglucerase Alfa for Injection specifically supplements the deficient glucocerebrosidase in the lysosomes of Gaucher disease patients through intravenous infusion.
Corporate Honors
01/
Seven Women Leaders from Qiming Venture Partners Portfolio Companies Named to Forbes China Lists
Recently, Forbes China released its 2025 Power Businesswomen 100 and 20 Rising Businesswomen lists. From Qiming Venture Partners portfolio companies, Xiaochun Cao, co-founder and general manager of Tigermed (300347.SZ, 03347.HK); Ni Li, vice chairwoman and chief operating officer of Bilibili (NASDAQ:BILI, 09626.HK); Ying Du, founder, chairwoman, and CEO of Zai Lab (NASDAQ:ZLAB, 09688.HK); Haoying Shi, founder and CEO of YourHealth; and Xiaoxin Qiu, founder and chairwoman of Axera, were named to the 2025 Forbes China Power Businesswomen 100 list. Zoe Ng, co-CEO and founder of moodytiger, and Hui Zhang, founder and CEO of Innoderm, were named to the 2025 Forbes China 20 Rising Businesswomen list.
Forbes China's Power Businesswomen 100 list examines female executives at publicly listed Chinese companies, female leaders of multinational corporations in China, and female founders of unicorn companies. Candidates are evaluated based on business performance, capital market performance, market scale, industry influence, and innovation. The 20 Rising Businesswomen list highlights female entrepreneurs who have demonstrated resilience and growth amid adversity, using their extraordinary courage and wisdom as inspiration to encourage more women to step forward, inject new vitality into the business world, and become an indispensable force in the era.
02/
Seven Qiming Venture Partners Portfolio Companies Named to ChinaVenture 2024 Rising 100 List
Recently, the 2024 ChinaVenture Rising 100 list was released. The list aims to identify the most innovative and fastest-growing technology companies of the year. Qiming Venture Partners portfolio companies Axera, StepFun, Nexteer Automotive, Ticore Biotech, Infinigence AI, Galaxy Universal, and Zhipu AI were named to the list.
ChinaVenture evaluated companies across three dimensions: external attention, industrial synergy, and industry influence, using a comprehensive process of application collection, survey research, market analysis, expert interviews, and data analysis to select the final list.
Past Issues
Qiming Weekly | Qiming Venture Partners Portfolio Company Updates Vol. 08, 2025
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management of $9.5 billion. Since its inception, the firm has focused on investing in early and growth-stage companies in the Technology and Consumer (T&C) and Healthcare sectors.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have gone public on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through mergers and acquisitions. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many Qiming Venture Partners portfolio companies have grown into the most influential companies in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ:WRD), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Berry Genomics (000710.SZ), SinoCellTech (688520.SH), Yuanxin Technology, ClinChoice, Belief BioMed, and Biren Technology.